NCT00002237已完成1 期
Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.
详细描述
Patients are given either BCX-35 or placebo for 14 or 28 days. Plasma viral load will be determined at the MTD.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV infection.
- •CD4 cell count greater than or equal to 300 cells/mm3 on 3 occasions prior to protocol treatment.
- •Plasma viral load by Roche Amplicor HIV Monitor assay greater than or equal to 2,000 RNA copies/ml and less than or equal to 50,000 RNA copies/ml on at least 2 occasions prior to protocol treatment.
- •Normal or non-diagnostic electrocardiogram.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Severe opportunistic infection or any other medical condition which in the opinion of the investigators is a contraindication to enrolling in this trial.
- •Severe lactose intolerance.
- •Concurrent Medication:
- •Concomitant therapy with other medications having primary renal excretion (other than 3TC, ddC, and d4T).
- •Prior Medication:
- •Ongoing dideoxyinosine or other antiretroviral therapy except ZDV, 3TC, ddC, d4T, saquinavir, ritonavir, indinavir, and nelfinavir within 2 weeks of study.
- •Participation in a study of any systemic experimental drug within the last 2 months.
- •- Ongoing (at least 4 weeks) stable dosage of zidovudine (ZDV) and lamivudine (3TC), ZDV and stavudine (d4T), ZDV and zalcitabine (ddC), d4T and 3TC, ZDV alone, or ddC alone, or in combination with saquinavir, ritonavir, indinavir, or nelfinavir.
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung CancerNon-Small-Cell Lung CarcinomaNCT01090830Holy Cross Hospital, Florida7
已完成
1 期
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell MalignanciesRecurrent or Refractory T/NK-cell MalignanciesNCT00823355Mundipharma K.K.24
已完成
1 期
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy ParticipantsHealthyNCT04669262BeiGene25
已完成
1 期
A Multiple Dose Safety Study of PEG-IFN in Healthy VolunteersHealthyNCT02125578Biogen69
已完成
1 期
Phase 1 Trial of Idebenone to Treat Patients With Friedreich's AtaxiaFriedreich AtaxiaNCT00078481National Institute of Neurological Disorders and Stroke (NINDS)16